产品说明书

Solifenacin

Print
Chemical Structure| 242478-37-1 同义名 : YM905 free base;YM905
CAS号 : 242478-37-1
货号 : A172890
分子式 : C23H26N2O2
纯度 : 98%
分子量 : 362.465
MDL号 : MFCD18910847
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(137.94 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • mAChR
描述 Solifenacin is a novel muscarinic receptor antagonist characterized by pKis of 7.6±0.056 for M1 receptors, 6.9±0.034 for M2 receptors, and 8.0±0.021 for M3 receptors. In studies involving murine submandibular gland cells, the effects of 100 nM Solifenacin and oxybutynin on Ca2+ mobilization induced by various doses of carbachol (CCh) are investigated. Unlike oxybutynin, which exhibits insurmountable antagonism, Solifenacin does not cause a parallel shift in the CCh dose-activation curve. The pKb values are determined to be 7.4±0.17 for Solifenacin and 8.8±0.21 for oxybutynin[1].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01122563 - Completed - Indonesia ... 展开 >> Bandung, Indonesia Jakarta, Indonesia Surabaya, Indonesia 收起 <<
NCT01018511 Benign Prostatic Hyperplasia ... 展开 >> Lower Urinary Tract Symptoms 收起 << Phase 3 Completed - -
NCT01457573 Lower Urinary Tract Symptoms Phase 4 Completed - United States, Texas ... 展开 >> The Methodist Hospital System Houston, Texas, United States, 77030 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.76mL

0.55mL

0.28mL

13.79mL

2.76mL

1.38mL

27.59mL

5.52mL

2.76mL
参考文献

[1]Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):97-103.

[2]Suzuki M, et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarctedrats. Eur J Pharmacol. 2005 Apr 4;512(1):61-6.